UPC vs. ABBV
UPC (Universe Pharmaceuticals INC) and ABBV (AbbVie Inc.) are both stocks. Both are in the Healthcare sector — UPC in Biotechnology, ABBV in Drug Manufacturers - General. Over the past 5 years, UPC returned -78.59%/yr vs 20.31%/yr for ABBV. At a 0.02 correlation, their price movements are largely independent.
Performance
UPC vs. ABBV - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, UPC achieves a 16.80% return, which is significantly higher than ABBV's 10.32% return.
UPC
- 1D
- -15.56%
- 1M
- 37.35%
- 6M
- 6.97%
- YTD
- 16.80%
- 1Y
- 17.11%
- 3Y*
- -85.04%
- 5Y*
- -78.59%
- 10Y*
- —
ABBV
- 1D
- -0.03%
- 1M
- 8.90%
- 6M
- 14.56%
- YTD
- 10.32%
- 1Y
- 33.06%
- 3Y*
- 26.16%
- 5Y*
- 20.31%
- 10Y*
- 19.35%
UPC vs. ABBV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
UPC Universe Pharmaceuticals INC | 16.80% | -84.39% | -97.98% | -76.90% | -11.31% | -68.92% |
ABBV AbbVie Inc. | 10.32% | 33.08% | 18.86% | -0.23% | 24.01% | 32.44% |
Correlation
The correlation between UPC and ABBV is 0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.01 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.01 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.02 |
Correlation (All Time) Calculated using the full available price history since Mar 23, 2021 | 0.02 |
Fundamentals
UPC:
$2.81M
ABBV:
$438.16B
UPC:
-$22.01
ABBV:
$2.05
UPC:
0.06
ABBV:
7.00
UPC:
0.04
ABBV:
16.00
UPC:
$40.88M
ABBV:
$62.82B
UPC:
$12.37M
ABBV:
$46.15B
UPC:
-$10.28M
ABBV:
$17.96B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
UPC vs. ABBV — Risk / Return Rank
UPC
ABBV
UPC vs. ABBV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Universe Pharmaceuticals INC (UPC) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| UPC | ABBV | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.24 | ||
| Sortino ratioReturn per unit of downside risk | +1.31 | ||
| Omega ratioGain probability vs. loss probability | 1.42 | 1.24 | +0.18 |
| Calmar ratioReturn relative to maximum drawdown | 0.23 | 1.92 | -1.69 |
| Martin ratioReturn relative to average drawdown | 0.32 | 4.26 | -3.94 |
Loading charts...
Drawdowns
UPC vs. ABBV - Drawdown Comparison
The maximum UPC drawdown since its inception was -99.99%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for UPC and ABBV.
Loading charts...
Drawdown Indicators
| UPC | ABBV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.99% | -45.09% | -54.90% |
Max Drawdown (1Y)Largest decline over 1 year | -76.24% | -17.32% | -58.92% |
Max Drawdown (3Y)Largest decline over 3 years | -99.91% | -20.74% | -79.17% |
Max Drawdown (5Y)Largest decline over 5 years | -99.98% | -21.92% | -78.06% |
Max Drawdown (10Y)Largest decline over 10 years | — | -45.09% | — |
Current DrawdownCurrent decline from peak | -99.98% | -5.01% | -94.97% |
Average DrawdownAverage peak-to-trough decline | -86.48% | -10.67% | -75.81% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 54.33% | 7.79% | +46.54% |
Volatility
UPC vs. ABBV - Volatility Comparison
Universe Pharmaceuticals INC (UPC) has a higher volatility of 164.58% compared to AbbVie Inc. (ABBV) at 10.47%. This indicates that UPC's price experiences larger fluctuations and is considered to be riskier than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| UPC | ABBV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 164.58% | 10.47% | +154.11% |
Volatility (6M)Calculated over the trailing 6-month period | 171.84% | 18.99% | +152.85% |
Volatility (1Y)Calculated over the trailing 1-year period | 343.82% | 25.84% | +317.98% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 221.41% | 23.33% | +198.08% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 217.05% | 25.87% | +191.18% |
Dividends
UPC vs. ABBV - Dividend Comparison
UPC has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 2.72%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ABBV AbbVie Inc. | 2.72% | 2.87% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% |
UPC Universe Pharmaceuticals INC | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
UPC vs. ABBV - Financials Comparison
This section allows you to compare key financial metrics between Universe Pharmaceuticals INC and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
UPC vs. ABBV - Profitability Comparison
UPC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Universe Pharmaceuticals INC reported a gross profit of 3.14M and revenue of 8.71M. Therefore, the gross margin over that period was 36.0%.
ABBV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, AbbVie Inc. reported a gross profit of 12.53B and revenue of 15.00B. Therefore, the gross margin over that period was 83.5%.
UPC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Universe Pharmaceuticals INC reported an operating income of -589.16K and revenue of 8.71M, resulting in an operating margin of -6.8%.
ABBV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, AbbVie Inc. reported an operating income of 4.73B and revenue of 15.00B, resulting in an operating margin of 31.6%.
UPC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Universe Pharmaceuticals INC reported a net income of -387.30K and revenue of 8.71M, resulting in a net margin of -4.5%.
ABBV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, AbbVie Inc. reported a net income of 699.00M and revenue of 15.00B, resulting in a net margin of 4.7%.
Frequently Asked Questions
UPC and ABBV have a correlation of 0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
UPC has higher volatility (164.58%) compared to ABBV (10.47%). In terms of maximum drawdown, UPC dropped -99.99% vs ABBV's -45.09%.
ABBV currently has the higher Sharpe Ratio (1.29 vs 0.05), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for UPC and ABBV
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer